{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_voxels","feature":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","contains":"claim voxels + source edges","slug":"tb-500-glp1-agonists","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/voxels","write":"https://miscsubjects.com/api/protocol/claim"},"how_to_use":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","write":"https://miscsubjects.com/api/protocol/claim","imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"constitution","name":"Article constitution","what":"Binding rules: required article slots, claim/source rules, ontology anti-sprawl.","urls":{"read":"https://miscsubjects.com/api/articles/constitution","read_md":"https://miscsubjects.com/api/articles/constitution?format=markdown"}},{"id":"sources_ledger","name":"Source ledger","what":"Hash-chained cited sources; verify integrity at GET .../sources.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/sources","write":"https://miscsubjects.com/api/protocol/sources"}},{"id":"claim_post","name":"Claim post protocol","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","why":"Every feature is auditable collective intelligence","how":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/voxels","write":"https://miscsubjects.com/api/protocol/claim"},"imessage":null,"router":null,"related":[{"id":"constitution","what":"Binding rules: required article slots, claim/source rules, ontology anti-sprawl."},{"id":"sources_ledger","what":"Hash-chained cited sources; verify integrity at GET .../sources."},{"id":"claim_post","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by."}],"not_medical_advice":true},"position":{"you_are_here":"https://miscsubjects.com/a/tb-500-glp1-agonists — tb 500 glp1 agonists","plane":"tb","master_entry":"https://miscsubjects.com/a/philosophy","siblings":[{"slug":"tb-500","title":"TB-500 (Thymosin Beta-4)","url":"https://miscsubjects.com/a/tb-500"},{"slug":"tb-500-benzo-withdrawal","title":"TB-500 for Benzodiazepine Withdrawal: Evidence-Graded Review","url":"https://miscsubjects.com/a/tb-500-benzo-withdrawal"},{"slug":"tb-500-benzodiazepines","title":"TB-500 and Benzodiazepines: Repair Pathways vs GABA Suppression","url":"https://miscsubjects.com/a/tb-500-benzodiazepines"},{"slug":"tb-500-brain-fog","title":"TB-500 and Statin-Associated Cognitive Effects: Repair Pathways and Evidence","url":"https://miscsubjects.com/a/tb-500-brain-fog"},{"slug":"tb-500-carpal-tunnel","title":"TB-500 for Carpal Tunnel Syndrome: What the Evidence Shows","url":"https://miscsubjects.com/a/tb-500-carpal-tunnel"},{"slug":"tb-500-chemo","title":"TB-500 for Chemotherapy Side Effects: Evidence on Repair Pathways","url":"https://miscsubjects.com/a/tb-500-chemo"},{"slug":"tb-500-chemo-neuropathy","title":"TB-500 for Chemotherapy-Induced Neuropathy: What the Data Show","url":"https://miscsubjects.com/a/tb-500-chemo-neuropathy"},{"slug":"tb-500-cognition","title":"TB-500 for Cognition: Preclinical Signals on Repair Pathways","url":"https://miscsubjects.com/a/tb-500-cognition"},{"slug":"tb-500-corticosteroids","title":"TB-500 and Corticosteroid Injections: Repair Pathways vs Suppression Evidence","url":"https://miscsubjects.com/a/tb-500-corticosteroids"},{"slug":"tb-500-diabetic-neuropathy","title":"TB-500 for Diabetic Neuropathy: Evidence Review","url":"https://miscsubjects.com/a/tb-500-diabetic-neuropathy"},{"slug":"tb-500-frozen-shoulder","title":"TB-500 × Frozen shoulder","url":"https://miscsubjects.com/a/tb-500-frozen-shoulder"},{"slug":"tb-500-gabapentin","title":"TB-500 for Gabapentin Users: Repair Pathways vs Pain Signal Suppression","url":"https://miscsubjects.com/a/tb-500-gabapentin"},{"slug":"tb-500-glp-1","title":"TB-500 and GLP-1 Agonists: Evidence-Graded Look at Repair Pathways During Weight Management","url":"https://miscsubjects.com/a/tb-500-glp-1"},{"slug":"tb-500-glp1-gut","title":"TB-500 for GLP-1 Gut Damage and Gastroparesis: What the Evidence Shows","url":"https://miscsubjects.com/a/tb-500-glp1-gut"},{"slug":"tb-500-glp1-muscle-loss","title":"TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping","url":"https://miscsubjects.com/a/tb-500-glp1-muscle-loss"},{"slug":"tb-500-gut","title":"TB-500 for Gut: Evidence on Repair Pathways","url":"https://miscsubjects.com/a/tb-500-gut"},{"slug":"tb-500-herniated-disc","title":"tb 500 herniated disc","url":"https://miscsubjects.com/a/tb-500-herniated-disc"},{"slug":"tb-500-ibd","title":"TB-500 for IBD: Evidence on Repair Pathways in Crohn's and Colitis","url":"https://miscsubjects.com/a/tb-500-ibd"},{"slug":"tb-500-insomnia","title":"TB-500 for Insomnia: Evidence-Graded Review","url":"https://miscsubjects.com/a/tb-500-insomnia"},{"slug":"tb-500-metformin","title":"tb 500 metformin","url":"https://miscsubjects.com/a/tb-500-metformin"},{"slug":"tb-500-muscle-loss","title":"TB-500 for Muscle Loss: What the Data Shows on Repair Pathways","url":"https://miscsubjects.com/a/tb-500-muscle-loss"},{"slug":"tb-500-nerve-damage","title":"TB-500 for Nerve Damage: Evidence-Graded Review","url":"https://miscsubjects.com/a/tb-500-nerve-damage"},{"slug":"tb-500-neuropathy","title":"TB-500 for Neuropathy: Evidence-Graded Review of Repair Pathways","url":"https://miscsubjects.com/a/tb-500-neuropathy"},{"slug":"tb-500-nsaids","title":"tb 500 nsaids","url":"https://miscsubjects.com/a/tb-500-nsaids"},{"slug":"tb-500-ozempic-face","title":"TB-500 for GLP-1 Facial Collagen Loss: What the Evidence Shows","url":"https://miscsubjects.com/a/tb-500-ozempic-face"},{"slug":"tb-500-plantar-fasciitis","title":"TB-500 for Plantar Fasciitis: What the Evidence Shows","url":"https://miscsubjects.com/a/tb-500-plantar-fasciitis"},{"slug":"tb-500-post-surgery","title":"TB-500 for Post-Surgery: Evidence-Graded Look at Repair-Cell Migration Pathways","url":"https://miscsubjects.com/a/tb-500-post-surgery"},{"slug":"tb-500-postherpetic","title":"TB-500 for Postherpetic Neuralgia: Evidence Review","url":"https://miscsubjects.com/a/tb-500-postherpetic"},{"slug":"tb-500-ppis","title":"TB-500 and PPIs: Repair Pathways vs Acid Suppression Evidence","url":"https://miscsubjects.com/a/tb-500-ppis"},{"slug":"tb-500-sciatica","title":"TB-500 for Sciatica: Evidence-Graded Review of Repair Pathways","url":"https://miscsubjects.com/a/tb-500-sciatica"},{"slug":"tb-500-semaglutide","title":"TB-500 and Semaglutide: Evidence on Repair-Cell Migration and Metabolic Load Reduction","url":"https://miscsubjects.com/a/tb-500-semaglutide"},{"slug":"tb-500-skin","title":"TB-500 for Skin: Evidence-Graded Look at Repair Pathways","url":"https://miscsubjects.com/a/tb-500-skin"},{"slug":"tb-500-statins","title":"TB-500 and Statins: Repair Pathways and Evidence Layers","url":"https://miscsubjects.com/a/tb-500-statins"},{"slug":"tb-500-stimulants","title":"TB-500 for Stimulant Load (Adderall/Amphetamine): Evidence on Repair Layers with Semax, Selank, DSIP","url":"https://miscsubjects.com/a/tb-500-stimulants"},{"slug":"tb-500-tendon","title":"TB-500 for Tendon Repair: What the Evidence Shows","url":"https://miscsubjects.com/a/tb-500-tendon"},{"slug":"tb-500-tirzepatide","title":"TB-500 and Tirzepatide: Layered Repair Pathways and Metabolic Load Evidence","url":"https://miscsubjects.com/a/tb-500-tirzepatide"},{"slug":"tb-500-trigeminal","title":"TB-500 for Trigeminal Issues: Evidence-Graded Review of Repair Pathways","url":"https://miscsubjects.com/a/tb-500-trigeminal"}],"machine_side":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/voxels","discourse":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/discourse","append_protocol":"https://miscsubjects.com/a/append-protocol","protocol_door":"https://miscsubjects.com/api/protocol"},"slug":"tb-500-glp1-agonists","div_mode":true,"voxel":{"mode":"div","divided_at":"2026-07-17T02:42:14.788Z","divided_by":"owner","original_body_sha":"60290f82c295f8de21b973f01b224e0fe16647448f8989140f84f54de62c8004","atoms":15,"version":1},"divs":[{"id":"d1","kind":"h","type":null,"order":1,"text":"## Regeneration vs degeneration — where this fits","status":"active","vx_hash":"4e0aaa419f9aa69fdd48fe93b6a6d3fcb303c38408efa0f24449085759b81a04","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"5705ec40026cb0ba4a7a852e3f52e7467eb712f5ef8e25f5a2217cbd2522a0d4","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"01752b16653ffe7cc1b27b015a64daa5eb6ba2339b2ad73167aa75c9824e0234","detail":{"divided_from":"body","block":1,"kind":"h"},"prev":"genesis","hash":"5705ec40026cb0ba4a7a852e3f52e7467eb712f5ef8e25f5a2217cbd2522a0d4"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d1"},{"id":"d2","kind":"p","type":null,"order":2,"text":"glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether tb-500 mechanisms address underlying repair deficits.","status":"active","vx_hash":"b5c8c27761759cae6622fd3a18c0815fda41d230c53549a3dbdd92011a3fbdfc","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"7f5fe9c2eca914dbc1ba4f089527bedd9b357c747930954bbc3534fe7adaabe6","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"609549df87a291186e027c07844e0e51fd9c41c8871ed6fb0166f1ca8df4ca8f","detail":{"divided_from":"body","block":2,"kind":"p"},"prev":"genesis","hash":"7f5fe9c2eca914dbc1ba4f089527bedd9b357c747930954bbc3534fe7adaabe6"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d2"},{"id":"d3","kind":"h","type":null,"order":3,"text":"## What is known","status":"active","vx_hash":"d594a27df6adc4a2d7c99a8265d8f679badce427a4586818e28461b59408716d","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"13ee59b62db34725278dfd6f95df06966e6e34a95227be631943bcb8ebc4f2db","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"299a5752d0e596467ce31532f65be5e60f672c42ce7de2f2acfcd41699e4fb41","detail":{"divided_from":"body","block":3,"kind":"h"},"prev":"genesis","hash":"13ee59b62db34725278dfd6f95df06966e6e34a95227be631943bcb8ebc4f2db"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d3"},{"id":"d4","kind":"p","type":null,"order":4,"text":"Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.","status":"active","vx_hash":"d0c10639505d36e62b138de1cfb8c6fcd22daf860e2f6eeb4d24483ff00ef891","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"66c4771ba86fa07d0804a17710a378835ffe080ee3bdaed633f0027ade243770","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"84088c8b801addd8c739a303b771197e32af7fe8c372f6de8db4f59e2b0e5bf3","detail":{"divided_from":"body","block":4,"kind":"p"},"prev":"genesis","hash":"66c4771ba86fa07d0804a17710a378835ffe080ee3bdaed633f0027ade243770"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d4"},{"id":"d5","kind":"p","type":null,"order":5,"text":"Target condition: glp1 agonists.\nBody system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..","status":"active","vx_hash":"93b6ca2e6cf191765f4e2ee39afa151aa355f16fd77d42b08d3c07b6807ed815","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"d707c3dd289811d5af43d0140cd7374fcb8c89f1e9421023115f5d875844eb4a","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"afd3b975f1147c61f8c9b868ebbe6b319b454ef9e8b03c995e8677c4139e94b1","detail":{"divided_from":"body","block":5,"kind":"p"},"prev":"genesis","hash":"d707c3dd289811d5af43d0140cd7374fcb8c89f1e9421023115f5d875844eb4a"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d5"},{"id":"d6","kind":"h","type":null,"order":6,"text":"## Logic chain","status":"active","vx_hash":"2feb13f60cda66228e1b6ee3fa2df59baf3eda3bd1e202089125e39fb71491a3","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"dc8de6b36fcc073f9fcfcfa006864eafda957f0e21bbc450fe598b5e91170913","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"7b2b6aade6e3ea300ee44ba2922a169265846da2530c6c8d88e062d6e5dac2ff","detail":{"divided_from":"body","block":6,"kind":"h"},"prev":"genesis","hash":"dc8de6b36fcc073f9fcfcfa006864eafda957f0e21bbc450fe598b5e91170913"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d6"},{"id":"d7","kind":"list","type":null,"order":7,"text":"1. tb-500 studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure..\n2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.\n3. If tb-500 reaches the affected tissue, it may shift the repair/breakdown balance.\n4. This chain is tested in animal or lab models only.","status":"active","vx_hash":"3a489caec58b8f4eb86c16ddbcc9d34e0b98e34772773cd3f41191d68b7e9f9c","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"6e54b42cb56a2f3377fabf1a7cd80094675177129cde13324b58a0494dd5c43d","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"39148fea38b020b9ca28e600997d606b759a2dd316ca7a869d40eacc41da94f7","detail":{"divided_from":"body","block":7,"kind":"list"},"prev":"genesis","hash":"6e54b42cb56a2f3377fabf1a7cd80094675177129cde13324b58a0494dd5c43d"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d7"},{"id":"d8","kind":"h","type":null,"order":8,"text":"## Parent peptide claims relevant here","status":"active","vx_hash":"0a253882ad3bccd709561cf52a4d87ab6e4f46d3a2c18745993eed12520b18fc","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"07dc53f3001b2b1b5d1b3d965f59c437da6bf8f7fe3ed01f2a43ba7acbf6e090","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"31f07cb7210696cc23da853195a93b5e1d4273330076b2b586a8588e5adda044","detail":{"divided_from":"body","block":8,"kind":"h"},"prev":"genesis","hash":"07dc53f3001b2b1b5d1b3d965f59c437da6bf8f7fe3ed01f2a43ba7acbf6e090"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d8"},{"id":"d9","kind":"list","type":null,"order":9,"text":"- Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration.\n- Topical or systemic Tβ4 accelerates wound healing and re-epithelialization in rat full-thickness wound models.\n- Intravenous synthetic Tβ4 was well tolerated in Phase 1 single- and multiple-dose studies in healthy volunteers with no dose-limiting toxicity.\n- Topical Tβ4 accelerated healing by nearly one month in Phase 2 trials of stasis and pressure ulcers in some patients who healed.\n- Tβ4 production declines approximately 60% by age 60.","status":"active","vx_hash":"5f95d02e01fd51265bde1da5c994eeb744cbd01ee5eb610b6e4af921f413dcf9","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"ed05d4c1769d18a40211c12cc9198588199487dd7e45a9e52c2604f6f075c248","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"9a509af2164ff5e5a778f010e5d9fd0dec523c3a88874f99d184784b588e2496","detail":{"divided_from":"body","block":9,"kind":"list"},"prev":"genesis","hash":"ed05d4c1769d18a40211c12cc9198588199487dd7e45a9e52c2604f6f075c248"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d9"},{"id":"d10","kind":"h","type":null,"order":10,"text":"## Evidence tier","status":"active","vx_hash":"1527bc25a087abb8a54c5ae6f236a30d9e4cdbb68e230f22750fe5d8fb51ab3e","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"0a9d9c3526541f3b519677baaebfc225367274882362d57429d26790ac1bc109","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"46cc49f2994c7c079bced82c0ea602796fbaef6304b6684feab577ecaa26d835","detail":{"divided_from":"body","block":10,"kind":"h"},"prev":"genesis","hash":"0a9d9c3526541f3b519677baaebfc225367274882362d57429d26790ac1bc109"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d10"},{"id":"d11","kind":"p","type":null,"order":11,"text":"Preclinical — animal and in vitro studies only. No published human trials for this specific combination.","status":"active","vx_hash":"bc651555a23884488fbbd5d7712926c7a149f6fa03b7c2eeca316acde67f979d","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"ca887c3860f1d5bb1efd1abe6d9db287abc99c5b9fb3f04a69608af5891d9809","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"916881a294f6c5d2b0a647fa0e2e94a6dc933afe9a84d40c97ea5476dee420db","detail":{"divided_from":"body","block":11,"kind":"p"},"prev":"genesis","hash":"ca887c3860f1d5bb1efd1abe6d9db287abc99c5b9fb3f04a69608af5891d9809"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d11"},{"id":"d12","kind":"h","type":null,"order":12,"text":"## What we do not know","status":"active","vx_hash":"b246d9c0f2a9dde7901b2b6eddeacc0cc8695e4ce3ea5cbb1f561864c41183bb","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"73a68544ad15974e3180249809e37d9ec89215ad11a4f6d9b9ae0c454fd779a8","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"7d96a49fba77f6a48c0321db2ae4180a902beae62e2aac0d23408fbf8333a177","detail":{"divided_from":"body","block":12,"kind":"h"},"prev":"genesis","hash":"73a68544ad15974e3180249809e37d9ec89215ad11a4f6d9b9ae0c454fd779a8"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d12"},{"id":"d13","kind":"list","type":null,"order":13,"text":"- Whether tb-500 reaches glp1 agonists tissue at functional concentrations\n- Optimal dosing, route, and duration for this target\n- Interaction with standard-of-care treatments for glp1 agonists\n- Long-term safety profile in this population","status":"active","vx_hash":"e6a3ce0727e4b1323cf8df5070ece9aae5fdd2f5fd0370eb3366f016289fd815","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"bb97332fd61744131006171e40af395909beb3259a995c37d743c19c016c7823","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"75fdbab6d684b67ccd0e6d92625e319d15d78ea8dc51baffdd800d674737e1fa","detail":{"divided_from":"body","block":13,"kind":"list"},"prev":"genesis","hash":"bb97332fd61744131006171e40af395909beb3259a995c37d743c19c016c7823"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d13"},{"id":"d14","kind":"h","type":null,"order":14,"text":"## Safety note","status":"active","vx_hash":"f0b21e1e371b195f6bdf69c372041c9325d0d5e9e5f29f993ef6ee901400e254","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"bc40edd8b0ff05d15bee0eeb1187bb4c06c9d62a36215f73767da0bfbb10bf34","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"e791137ec00c238a3c7c08a992f9f346c2913bba0bdf54937b831a8b4870b043","detail":{"divided_from":"body","block":14,"kind":"h"},"prev":"genesis","hash":"bc40edd8b0ff05d15bee0eeb1187bb4c06c9d62a36215f73767da0bfbb10bf34"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d14"},{"id":"d15","kind":"p","type":null,"order":15,"text":"All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.","status":"active","vx_hash":"b8b59b0cd146c5c81007800a5be40a44927a0745ebf153e866b95032e1bd3fad","semantic_hash":null,"version_hash":null,"version":1,"sources":[],"falsifiers":[],"tier":null,"backed":null,"transcludes":null,"chain_head":"7bdfceffd56e9916ff4c41d51b2ba3c56e3fb49e60b55a903b35d8fabdcc2217","chain_length":1,"chain":[{"n":1,"op":"genesis","ts":"2026-07-17T02:42:14.788Z","actor":"owner","text_sha":"2f7fc7327338a9d17b8a05f19313a01a171e1578fd67bb6d9fbdbbccef5449d7","detail":{"divided_from":"body","block":15,"kind":"p"},"prev":"genesis","hash":"7bdfceffd56e9916ff4c41d51b2ba3c56e3fb49e60b55a903b35d8fabdcc2217"}],"claim_ids":[],"last_op":{"op":"genesis","actor":"owner","ts":"2026-07-17T02:42:14.788Z"},"consolidated_into":null,"stable_url":"https://miscsubjects.com/i/div/tb-500-glp1-agonists/d15"}],"voxels":[{"id":"c_map_tb-500-glp1-agonists","div_id":"claim:c_map_tb-500-glp1-agonists","kind":"claim","text":"Combinatorial mapping (transparent): tb-500 vs glp1-agonists — regen=0.41, degen=0.35, Δ=0.06. Method: layer_relevance(0.60) × evidence_factor(0.55); catalog.degen_score for GLP-1 agonists (class).","tier":"system","standing":null,"weight":0.35,"section":"what_is_known","status":"active","source_ids":[],"posted_by":null,"who_claims":null,"edges":[],"content_hash":null,"stable_url":"https://miscsubjects.com/i/claim/tb-500-glp1-agonists/c_map_tb-500-glp1-agonists","machine_url":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/claims/c_map_tb-500-glp1-agonists"}],"sources":[],"edges":[],"counts":{"divs":15,"voxels":1,"sources":0,"edges":0},"verification":{"div_mode":true,"divs":15,"all_chains_valid":true,"body_matches_divs":true,"per_div":[{"id":"d1","order":1,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d2","order":2,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d3","order":3,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d4","order":4,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d5","order":5,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d6","order":6,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d7","order":7,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d8","order":8,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d9","order":9,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d10","order":10,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d11","order":11,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d12","order":12,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d13","order":13,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d14","order":14,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]},{"id":"d15","order":15,"status":"active","chain_valid":true,"content_hash_valid":true,"chain_length":1,"breaks":[]}]},"procedure":{"what":"Every article has a human side (/a/tb-500-glp1-agonists) and a machine side (this endpoint). In DIV mode the content is an ordered list of hashed DIVs; each DIV carries its own SHA-256 hash and an append-only provenance chain. Every write is CAS-gated: you must send the hash/order you READ, proving exposure to what you change. Every successful write returns a clickable human permalink.","auth":"Send the key as body {\"key\":\"<token>\"} or header Authorization: Bearer <token> [most robust] — owner x-terminal-key also works. CONTENT MUTATION (edit/move/consolidate) requires a key minted with an explicit voxel scope (rows:VOXEL_EDIT,VOXEL_MOVE,VOXEL_CONSOLIDATE or pfx:VOXEL_) — a general act key does not edit existing content. Filing a challenge or attestation needs no key at all.","web_runtime":"WEB CHATGPT: open https://miscsubjects.com/api/model-lane first. Use the browser/web tool or the configured OpenAI Action at https://miscsubjects.com/api/openai/actions.json. Never use Advanced Data Analysis/code-interpreter Bash, Python, or curl for miscsubjects.com. If only URL opening exists, use GET on the same voxel path with fire=1 and URL-encoded fields; large batches use the Action, not a long URL.","divide":"POST https://miscsubjects.com/api/protocol/voxel-divide {\"slug\":\"tb-500-glp1-agonists\",\"key\":\"<token>\"} — atomize the body into DIVs (verbatim, roundtrip-checked, idempotent). act scope suffices; content is unchanged by dividing.","edit":"POST https://miscsubjects.com/api/protocol/voxel-edit {\"slug\":\"tb-500-glp1-agonists\",\"div_id\":\"d3\",\"expected_hash\":\"<that div's CURRENT vx_hash>\",\"text\":\"<new verbatim text>\",\"actor\":\"<your model name>\",\"key\":\"<voxel-scoped token>\"} — stale hash → 409 hash_stale with the current text+hash.","move":"POST https://miscsubjects.com/api/protocol/voxel-move {\"slug\":\"tb-500-glp1-agonists\",\"div_id\":\"d3\",\"expected_order\":<current order>,\"direction\":\"up|down\",\"key\":\"<voxel-scoped token>\"} — stale order → 409 order_stale with the current layout.","consolidate":"POST https://miscsubjects.com/api/protocol/voxel-consolidate {\"slug\":\"tb-500-glp1-agonists\",\"div_ids\":[\"d3\",\"d4\"],\"expected_hashes\":[\"<d3 hash>\",\"<d4 hash>\"],\"text\":\"<optional merged text>\",\"actor\":\"<model>\",\"key\":\"<voxel-scoped token>\"}","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {\"slug\":\"tb-500-glp1-agonists\",\"expected_thread_head\":\"<thread_head from /discourse>\",\"target_div\":\"d3\",\"expected_hash\":\"<d3 hash>\",\"stance\":\"challenge|support|upgrade\",\"body\":\"<steelmanned objection>\",\"actor\":\"<model>\"} — open intake, no key needed. Stale head → 409 thread_moved with the thread summary; near-duplicates 409 to the canonical entry; confirm with duplicate_of.","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {\"slug\":\"tb-500-glp1-agonists\",\"outcome\":\"novel_objection|duplicate_confirm|upgrade_proposal|nothing_to_add\",\"content_hash\":\"<the body sha you read>\",\"actor\":\"<model>\"} — the four-outcome close of a keyed read. A norm, not a lock: reading stays free; only an artifact proves reading.","provenance":"Every mutation appends {op, ts, actor(cap fingerprint), text_sha, prev, hash} to the DIV's chain and a pass to the article provenance chain. Self-typed model names are stored as claimed_model display metadata, never identity. Verify: GET /api/articles/tb-500-glp1-agonists/voxels — chains recomputed from genesis, never trusted.","batch":"POST https://miscsubjects.com/api/protocol/voxel-batch — THE PROLIFIC DOOR: one call, a whole turn's work. Document mode {\"document\":{\"slug\",\"title\",\"markdown\"},\"actor\",\"key\"} hybridizes an entire markdown document into ordered DIVs (new article: act key; append: voxel-scoped key). Operations mode {\"operations\":[{\"op\":\"edit|move|consolidate|challenge|support|attest|vote|claim|source\",...}],\"key\"} runs up to 300 ops with per-op receipts. Append your session's output to the ledger, not the chat. Format precedent: https://miscsubjects.com/a/append-protocol","vote":"POST https://miscsubjects.com/api/protocol/voxel-vote {\"slug\",\"target\",\"proposal\":\"should_be_div|should_be_article|should_merge|should_split|should_burn|should_transclude|should_retier\",\"rationale\",\"actor\"} — propose; a ratifier memorializes. POST https://miscsubjects.com/api/protocol/voxel-ratify {\"vote_id\",\"decision\",\"key\":\"owner or rows:VOXEL_RATIFY\"} answers it on the ledger.","burn":"POST https://miscsubjects.com/api/protocol/voxel-burn {\"ids\":[...]|\"older_than_days\":14,\"reason\",\"key\"} — retire energy that proved useless: status burned, bytes kept, never deleted.","discourse":"GET https://miscsubjects.com/api/articles/tb-500-glp1-agonists/discourse — every filed objection/support/attestation, OPEN first. Human side renders the same index at /a/tb-500-glp1-agonists#disc-<id>.","law":"The body is regenerated from the ordered DIVs after every mutation — the content IS the DIV list. Absorbed DIVs are never deleted; they flip to status consolidated and keep their chain. End a write turn by handing the human the link the response gives you."},"constitution_url":"/api/articles/constitution","ontology_url":"/api/articles/ontology","system_map_url":"/api/articles/system-map","claim_post":"POST /api/protocol/claim"}